With more than 18 years of experience in drug discovery, Chris has worked at the intersection of chemistry, biology, and computation, developing both clinical candidates and innovative technologies aimed at treating unmet medical needs.
At GSK, Chris was part of the pioneering team behind targeted protein degradation. Later, at BenevolentAI, he played a key role in developing the first biologically-aware knowledge graphs, which led to the identification of novel disease targets, including for Ulcerative Colitis, Idiopathic Pulmonary Fibrosis, and MASH.
In late 2024, he founded Ternary Therapeutics, a company focused on building a computational platform for designing molecular glues — a cutting-edge approach in small molecule drug development.
Chris brings a rare blend of deep scientific expertise and visionary thinking, making him the ideal person to lead this timely and important discussion on the role of AI in next-generation drug discovery.